Cipla enters into agreement with MannKind Corporation for Afrezza

10 May 2018 Evaluate

Cipla has entered into an exclusive marketing and distribution agreement with US-based MannKind Corporation for Afrezza in India. Afrezza is the only USFDA approved inhaled insulin available for patients suffering from diabetes.

Under the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI). Cipla will also be responsible for all marketing and sales activities of Afrezza in India. MannKind is responsible for supplying Afrezza to Cipla.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1329.25 -22.60 (-1.67%)
04-Mar-2026 10:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1733.55
Dr. Reddys Lab 1281.00
Cipla 1329.25
Zydus Lifesciences 896.90
Lupin 2271.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×